Windtree Therapeutics issued Hong Kong patent for istaroxime

Windtree Therapeutics (WINT) announced the issuance of an istaroxime patent for Hong Kong. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure.” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of AHF. The application number is 62021023600. The Notice of Publication of the Registration and Grant has a date of October 9, 2024 and will expire in 2039. The patent for mainland China was granted earlier this year. Windtree’s licensing partner, Lee’s Pharmaceutical, is planning a Phase 3 program in acute heart failure for its Greater China territory. In alignment with the licensing agreement, Lee’s is funding all trials and development conducted in their region. Windtree is collaborating with Lee’s on the Phase 3 program and has final signing authority on the protocol. Acute heart failure is the #1 cause of hospitalization in patients greater than65 years of age in many regions of the world and as Windtree advances its cardiogenic shock program globally, Lee’s is progressing the acute heart failure intended indication. Istaroxime is a novel, first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining renal function with a generally favorable safety profile. Istaroxime has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock due to heart failure.